Stockreport

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF • Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- [Read more]